What is a stock summary page? Click here for an overview.
Business Description
Macrogenics Inc
NAICS : 325412
SIC : 2834
ISIN : US5560991094
Compare
Compare
Traded in other countries / regions
MGNX.USAM55.Germany Index Membership
Russell 2000Russell 3000 IPO Date
2013-10-10Description
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 5.38 | |||||
| Equity-to-Asset | 0.44 | |||||
| Debt-to-Equity | 0.32 | |||||
| Debt-to-EBITDA | -0.65 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -5.44 | |||||
| Beneish M-Score | -1.68 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 23.4 | |||||
| 3-Year EBITDA Growth Rate | 34 | |||||
| 3-Year EPS without NRI Growth Rate | 23.2 | |||||
| 3-Year FCF Growth Rate | 22.8 | |||||
| 3-Year Book Growth Rate | -22.1 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | -19.71 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 6.33 | |||||
| 9-Day RSI | 13.45 | |||||
| 14-Day RSI | 19.12 | |||||
| 3-1 Month Momentum % | -23.84 | |||||
| 6-1 Month Momentum % | -22.88 | |||||
| 12-1 Month Momentum % | -83.29 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.92 | |||||
| Quick Ratio | 3.92 | |||||
| Cash Ratio | 3.63 | |||||
| Days Inventory | 46.85 | |||||
| Days Sales Outstanding | 18.13 | |||||
| Days Payable | 201.8 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.8 | |||||
| Shareholder Yield % | -0.84 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 91.71 | |||||
| Operating Margin % | -74.54 | |||||
| Net Margin % | -45.14 | |||||
| FCF Margin % | -48.59 | |||||
| ROE % | -60.58 | |||||
| ROA % | -26.28 | |||||
| ROIC % | -156.52 | |||||
| 3-Year ROIIC % | -578.77 | |||||
| ROC (Joel Greenblatt) % | -149.6 | |||||
| ROCE % | -32.8 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.53 | |||||
| PB Ratio | 0.68 | |||||
| Price-to-Tangible-Book | 0.68 | |||||
| EV-to-EBIT | 1.09 | |||||
| EV-to-EBITDA | 1.23 | |||||
| EV-to-Revenue | -0.48 | |||||
| EV-to-FCF | 0.98 | |||||
| Price-to-GF-Value | 0.16 | |||||
| Price-to-Median-PS-Value | 0.07 | |||||
| Price-to-Net-Current-Asset-Value | 1.11 | |||||
| Price-to-Net-Cash | 1.42 | |||||
| Earnings Yield (Greenblatt) % | 91.74 | |||||
| FCF Yield % | -90.67 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MGNX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Macrogenics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 148.339 | ||
| EPS (TTM) ($) | -1.08 | ||
| Beta | 1.43 | ||
| 3-Year Sharpe Ratio | -0.02 | ||
| 3-Year Sortino Ratio | -0.03 | ||
| Volatility % | 72.68 | ||
| 14-Day RSI | 19.12 | ||
| 14-Day ATR ($) | 0.17642 | ||
| 20-Day SMA ($) | 2.0775 | ||
| 12-1 Month Momentum % | -83.29 | ||
| 52-Week Range ($) | 1.26 - 19.5408 | ||
| Shares Outstanding (Mil) | 63.09 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Macrogenics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Macrogenics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Macrogenics Inc Frequently Asked Questions
What is Macrogenics Inc(MGNX)'s stock price today?
The current price of MGNX is $1.26. The 52 week high of MGNX is $19.54 and 52 week low is $1.26.
When is next earnings date of Macrogenics Inc(MGNX)?
The next earnings date of Macrogenics Inc(MGNX) is 2025-05-09 Est..
Does Macrogenics Inc(MGNX) pay dividends? If so, how much?
Macrogenics Inc(MGNX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers